Mary F. Lampe |
|
University of Washington School of Medicine Microbiology Adjunct Associate ProfessorAppointed: 1998 University of Washington School of Medicine Laboratory Medicine Director, Medical Technology ProgramAppointed: 1998 University of Washington School of Medicine Laboratory Medicine Associate ProfessorAppointed: 1989 University of Washington School of Medicine Medicine Allergy and Infectious Diseases Associate ProfessorAppointed: 1989 |
Mailing AddressBox 357110/NW120 University of Washington Seattle, Washington 98195United States | Contact Information |
Qualifications
Ph.D., University of North Carolina at Chapel Hill, 1984.
M.S., University of Washington, Microbiology, 1976.
B.S., University of Washington, Medical Technology, 1968.
Expertise and Research Interests
Research in this laboratory focuses on the molecular analysis of the pathogenesis, immune response to, and intervention in Chlamydia trachomatis infection. Specific research projects include:
1. Cloning, DNA sequence determination, and immunologic and genetic analysis of a putative C. trachomatis cytolysin. A DNA fragment from the Chlamydia chromosome was cloned and identified by its ability to direct hemolysis in a non-hemolytic E. coli. The DNA sequence of the fragment was determined and shown tohave homology to a family of putative membrane proteins on C. trachomatis and a rickettsial immunoprotective outer membrane protein. Future projects include raising polyclonal antibodies against the protein, using them to determine the location of the protein in C. trachomatis, and testing whether the antibodies block chlamydial infectivity.
2. Characterization of murine cytotoxic T lymphocyte lines which are specific for, and able to lyse, Chlamydia infected cells,. These cells recognize a peptide oninfected cells presented by the classical murine MHC class I molecule H-2Ld. They afford partial protection when adoptively transferred into infected mice. Current efforts suggest that inoculation strategies which prime a cytotoxic T-cell response against C. trachomatis can effect broad protection against most Chlamydia serovars. Future goals include determination of the molecular identity of epitopes which elicit a protective CTL response and whether such protection can be achieved in genetically diverse mice. These studies are being carried out in collaboration with Dr. Michael Starnbach at Harvard University.
3. In vitro sensitivity of Chlamydia trachomatis to currently available microbicidal compounds and novel naturally-occurring antimicrobicides. The goal is to identify microbicides that prevent infections by C. trachomatis when applied vaginally. Chlorhexidine gluconate, novel lipids from human milk, and a cecropin peptide are currently being tested for their antimicrobial action on Chlamydia. These studies are being conducted with researchers at the UW, the University of Pittsburgh, and the NYS Institute for Basic Research.
Other projects include identification of eukaryotic receptors involved in C. trachomatis attachment, development of a chlamydial plasmid transformation system, and identification of additional C. trachomatis virulence factors.
1. Cloning, DNA sequence determination, and immunologic and genetic analysis of a putative C. trachomatis cytolysin. A DNA fragment from the Chlamydia chromosome was cloned and identified by its ability to direct hemolysis in a non-hemolytic E. coli. The DNA sequence of the fragment was determined and shown tohave homology to a family of putative membrane proteins on C. trachomatis and a rickettsial immunoprotective outer membrane protein. Future projects include raising polyclonal antibodies against the protein, using them to determine the location of the protein in C. trachomatis, and testing whether the antibodies block chlamydial infectivity.
2. Characterization of murine cytotoxic T lymphocyte lines which are specific for, and able to lyse, Chlamydia infected cells,. These cells recognize a peptide oninfected cells presented by the classical murine MHC class I molecule H-2Ld. They afford partial protection when adoptively transferred into infected mice. Current efforts suggest that inoculation strategies which prime a cytotoxic T-cell response against C. trachomatis can effect broad protection against most Chlamydia serovars. Future goals include determination of the molecular identity of epitopes which elicit a protective CTL response and whether such protection can be achieved in genetically diverse mice. These studies are being carried out in collaboration with Dr. Michael Starnbach at Harvard University.
3. In vitro sensitivity of Chlamydia trachomatis to currently available microbicidal compounds and novel naturally-occurring antimicrobicides. The goal is to identify microbicides that prevent infections by C. trachomatis when applied vaginally. Chlorhexidine gluconate, novel lipids from human milk, and a cecropin peptide are currently being tested for their antimicrobial action on Chlamydia. These studies are being conducted with researchers at the UW, the University of Pittsburgh, and the NYS Institute for Basic Research.
Other projects include identification of eukaryotic receptors involved in C. trachomatis attachment, development of a chlamydial plasmid transformation system, and identification of additional C. trachomatis virulence factors.
Other Expertise
Academic Experience:
Manuscript reviewer:
Infection and Immunity;
Journal of Infectious Diseases;
Journal of Clinical Microbiology;
Microbiological Reviews;
Obstetrics and Gynecology;
Genitourinary Medicine;
Antimicrobial Agents and Chemotherapy
Manuscript reviewer:
Infection and Immunity;
Journal of Infectious Diseases;
Journal of Clinical Microbiology;
Microbiological Reviews;
Obstetrics and Gynecology;
Genitourinary Medicine;
Antimicrobial Agents and Chemotherapy
Keywords
COS Keywords:
Bacteria, Bacteriology, Biochemistry, DNA, Gene Cloning, Inflammation, Microbial Pathogenesis, Sexually Transmitted Diseases, Tumor Immunology.Additional Terms:
Bacteria, Bacterial Disease, Chlamydia, Chlamydia Trachomatis, DNA, Drug Study, Infectious Disease, Inflammation, Microbial Pathogenesis, Virulence Factors.Languages
(Reading, Writing, Speaking)
French: (Basic, Basic, Functional)
Amharic: (None, None, Basic)
Memberships
Academy of Clinical Laboratory Physicians and Scientists
American Society for Clinical Laboratory Science
American Society for Microbiology
Association for Women in Science
Northwest Branch, American Society for Microbiology
Previous Positions
1988-1989, Postdoctoral Fellow,
University of Washington
1985-1987, Postdoctoral Fellow,
Harvard University
1984-1985, Institut Pasteur (France), Postdoctoral Fellow
1982, University of North Carolina, Chapel Hill, Carolina Workshop on DNA Sequencing and General DNA Technology, Molecular Biology and Biotechnology, Teaching Assistant
Funding Received
- National Institutes of Health (NIH): Chlamydia trachomatis laboratory core D, $142,881, Mar 1, 1995 to Mar 31, 1999.
- National Institutes of Health (NIH): Univ. of Wash. Sex. Trans. Dis. Cooperative Research Center Project 5, Jul 1, 1995 to Jun 30, 1999.
Publications
- Lampe M F, Ballweber L M, Stamm W E, Susceptibility of Chlamydia trachomatis to chlorhexidine gluconate gel., Antimicrobial Agents and Chemotherapy, 42(7), 1726-30, July 1998
- Lampe M F, Ballweber L M, Isaacs C E, Patton D L, Stamm W E, Killing of Chlamydia trachomatis by novel antimicrobial lipids adapted from compounds in human breast milk., Antimicrobial Agents and Chemotherapy, 42(5), 1239-44, May 1998
- Lampe, MF, Ballweber, LM, Stamm, WE, Susceptibility of Chlamydia trachomatis to Chlorhexidine Gluconate Gel, Antimicrobial Agents and Chemotherapy, 42, 1726-30, 1998
- Lampe, MF, Ballweber, LM, Isaacs, CE, Klebanoff, SJ, Stamm, WE, Susceptibility of Chlamydia trachomatis to Novel Topical Microbicides, Chlamydial Infections, Proceedings of the Ninth International Symposium on Human Chlamydial Infections, 1998
- Lampe, MF, Ballweber, LM, Stamm, WE, Cloning and Sequence Analysis of a Putative Cytolysin from Chlamydia trachomatis, Chlamydial Infections, Proceedings of the Ninth International Symposium on Human Chlamydial Infections, 1998
- Lampe, MF, Ballweber, LM, Isaacs, CE, Patton, DL, Stamm WE, Killing of Chlamydia trachomatis by Novel Antimicrobial Lipids Adapted from Compounds in Human Breast Milk, Antimicrobial Agents and Chemotherapy, 42, 1239-44, 1998
- Lampe, MF, Wilson, CB, Bevan, MJ, Starnbach, MN, The Role of Interferon-g in the Resolution of Chlamydia trachomatis Infection by Cytotoxic T-lymphocytes, Chlamydial Infections, Proceedings of the Ninth Internationa, 1998
- Lampe M F, Wong K G, Kuehl L M, Stamm W E, Chlamydia trachomatis major outer membrane protein variants escape neutralization by both monoclonal antibodies and human immune sera, Infection and Immunity, 65(1), 317-9, January 1997
- Lampe, M.F., Ballweber, L.M., Borders, M.A., Isaacs, C.E., Stamm, W.E, A New Approach to Control Sexually Transmitted Diseases: Effect of Novel Topical Microbicides on Chlamydia trachomatis, Proceedings, Third Meeting of the European Society for Chlamydia Research, 1996
- Starnbach M N, Bevan M J, Lampe M F, Murine cytotoxic T lymphocytes induced following Chlamydia trachomatis intraperitoneal or genital tract infection respond to cells infected with multiple serovars, Infection and Immunity, 63(9), 3527-30, September 1995
- Lampe M F, Wong K G, Stamm W E, Sequence conservation in the major outer membrane protein gene among Chlamydia trachomatis strains isolated from the upper and lower urogenital tract, Journal of Infectious Diseases, 172(2), 589-92, August 1995
- Bauwens J E, Lampe M F, Suchland R J, Wong K, Stamm W E, Infection with Chlamydia trachomatis lymphogranuloma venereum serovar L1 in homosexual men with proctitis: molecular analysis of an unusual case cluster, Clinical Infectious Diseases, 20(3), 576-81, March 1995
- Starnbach M N, Bevan M J, Lampe M F, Protective cytotoxic T lymphocytes are induced during murine infection with Chlamydia trachomatis., Journal of Immunology, 153(11), 5183-9, 1 Dec 1994
- Lampe M F, Stamm W E, Purification of Chlamydia trachomatis strains in mixed infection by monoclonal antibody neutralization, Journal of Clinical Microbiology, 32(2), 533-5, February 1994
- Workowski K A, Lampe M F, Wong K G, Watts M B, Stamm W E, Long-term eradication of Chlamydia trachomatis genital infection after antimicrobial therapy. Evidence against persistent infection [see comments] [published erratum appears in JAMA 1994 Feb 2;271(5):, Jama, 270(17), 2071-5, 3 Nov 1993
- Patton D L, Wolner-Hanssen P, Zeng W, Lampe M, Wong K, Stamm W E, Holmes K K, The role of spermatozoa in the pathogenesis of Chlamydia trachomatis salpingitis in a primate model, Sexually Transmitted Diseases, 20(4), 214-9, Summer 1993
- Lampe M F, Suchland R J, Stamm W E, Nucleotide sequence of the variable domains within the major outer membrane protein gene from serovariants of Chlamydia trachomatis, Infection and Immunity, 61(1), 213-9, January 1993
- Starnbach, M.N., M.J. Bevan, M.F. Lampe, 'Protective Cytotoxic T-Lymphocytes are Induced During Murine Infection with 'Chlamydia Trachomatis,' J. Immunol., 153:5183-5189, 1994
- Lampe, M.F., L.M. Kuehl, K.G. Wong, W.E. Stamm, ''Chlamydia Trachomatis' Major Outer Membrane Protein Variants Escape Neutralization by Polyclonal Human Immune Sera,' Chlamydial Infections, Proceedings of the Eighth International Symposium on Human Chlamydial Infections, J. Schachter, J. Chernesky, T. Grayston, R.B. Jones, J. Orifila, G. Ridgway, R.S. Stephens, W.E. Stamm (eds.), New York: Cambridge University Press, 1994
- Lampe, MF, Wilson, CB, Bevan, MJ, Starnbach, MN, The Role of Interferon-g in the Resolution of Chlamydia trachomatis Infection by Cytotoxic T-lymphocytes, Journal of Immunology, in press
Profile Details
Last Updated: 9/11/1998
COS Expertise ID #308519
Reference this profile directly: http://myprofile.cos.com/lampem19
Individual Expertise profile of Mary F. Lampe, Copyright Mary F. Lampe.
© COS ExpertiseTM, 2008, ProQuest LLC All rights reserved.